Abcam, ab236008, Anti-NR1D1 + NR1D2 / RVR antibody [EPR10376] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal NR1D1 antibody. Carrier free. Suitable for WB, IHC-P, ICC/IF, Flow Cyt (Intra) and reacts with Human, Mouse, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR10376,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, ICC/IF, IHC-P, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab236008 is the carrier-free version of
ab174309
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
NR1D1 and NR1D2 also known as RVR (Rev-erb) act as nuclear receptors involved in transcriptional regulation. Each has a mass ranging from 65 to 70 kDa. You can find NR1D1 and NR1D2 broadly expressed in multiple tissues with liver adipose tissue and muscles showing higher expression. These receptors play a role in regulating circadian rhythms and metabolism by repressing target gene expression through DNA binding.
Biological function summary
These nuclear receptors function as transcription repressors and are an essential part of the circadian clock complex. They interact with specific promoter regions competing with retinoic acid receptor-related orphan receptors to suppress gene transcription. Additionally they influence processes such as lipid metabolism and energy homeostasis by regulating genes involved in these pathways.
Pathways
NR1D1 and NR1D2 operate in the circadian rhythm pathway and lipid metabolism pathway. They directly interact with components of the core clock machinery such as BMAL1 and CLOCK proteins to maintain circadian rhythm stability. By repressing genes like lipogenic enzymes they facilitate optimal lipid metabolism. ROR proteins are closely linked to their function creating a feedback loop within these pathways.
NR1D1 and NR1D2 have links to metabolic diseases and mood disorders. Abnormal expression levels or mutations can result in conditions such as obesity and depression due to their important role in maintaining metabolic balance and circadian regulation. Dysfunctions in these receptors can engage E4BP4 affecting immune response and neuroinflammation in these disorders. Engaging these pathways opens potential therapeutic avenues for managing related conditions.